Skip to main content
SC
SignalCast
Start Free
PM

Paul Matisse

**m&a Market DynamicsBiotech Hangout Episode 193 Covers Xbi**biotech Market Bifurcation**clinical Trial Design Risk**psychedelics Durability Signal
6episodes
1podcast

Featured On 1 Podcast

Biotech Hangout

Biotech Hangout

6 episodes

All Appearances

6 episodes
Biotech Hangout

Episode 193 - August 14, 2026

Biotech Hangout
59 minCohost

AI Summary

→ WHAT IT COVERS Biotech Hangout Episode 193 covers XBI market performance, two high-profile clinical failures (10x Genomics HFpEF trial, Siona CF trial), the Jazz Pharmaceuticals $1.3B Actio acquisition, positive psychedelics phase three data from Definium, and the ongoing US-China biotech protectionism debate. → KEY INSIGHTS - **Biotech Market Bifurcation:** XBI outperforms the broader market year-to-date, but returns are highly uneven. Funds with mandatory short exposure struggled as heavily-shorted stocks like Kinetics and Apogee were acquired without warning. Investors tracking biotech should monitor short interest in liquid, catalyst-light names, as unexpected takeouts can rapidly compress those positions. - **Clinical Trial Design Risk:** Siona's CF trial enrolled only 14 patients and measured sweat chloride reduction as a pharmacodynamic proxy, targeting a 10 mmol threshold. Results showed only 1 mmol reduction, a 90% stock decline followed. Small proof-of-concept studies using surrogate biomarkers carry outsized binary risk; investors should scrutinize sample size and endpoint predictiveness before building positions. - **Psychedelics Durability Signal:** Definium's phase three generalized anxiety disorder study showed a statistically significant effect size at 12 weeks post single-dose LSD administration, supporting once-quarterly or less frequent dosing. FDA's psych division now requires anxiety trials to exclude patients with comorbid depression to confirm pseudo-specificity, a design standard that future psychedelics programs should incorporate proactively. - **China Partnership Strategy:** Revolution Medicines structured a deal with BioNTech subsidiary B1 exchanging China commercialization rights for its RAS portfolio in return for clinical collaboration access to B1's PRMT5 and EGFR-MET trispecific assets. Companies with strong pipelines can use regional rights as non-dilutive currency to access complementary mechanisms without building costly local commercial infrastructure. - **Post-Acquisition Safety Risk:** Amgen's Tavneos faced EMA withdrawal after evidence emerged that ChemoCentryx, acquired in 2022, had unblinded trial data, reclassified nine patients as responders, and filed on manipulated p-values. Acquirers should conduct independent statistical audits of pivotal trial patient-level datasets during due diligence, not solely relying on regulatory submission summaries or management representations. → NOTABLE MOMENT Definium's phase three anxiety trial deliberately excluded patients with comorbid depression to prove the drug's effect was anxiety-specific, not a byproduct of improving mood. Despite this population de-enrichment, the effect size remained large at 12 weeks post-dose, a result the panel described as difficult to explain mechanistically. 💼 SPONSORS None detected 🏷️ XBI Market Sentiment, Clinical Trial Failures, Psychedelic Therapeutics, China Biotech Partnerships, M&A Due Diligence

Read Full SummaryListen
Biotech Hangout

Episode 188 - July 10, 2026

Biotech Hangout
61 minCohost

AI Summary

→ WHAT IT COVERS Biotech Hangout Episode 188 covers FDA regulatory shifts including CRL transparency rollbacks and lowered approval bars for rare diseases, the failed AstraZeneca/Ionis eplontersen TTR cardiomyopathy trial, Vertex's $9B Crinetics acquisition, Anthropic's Claude for Science AI platform, and upcoming Biogen anti-tau Alzheimer's data at AAIC London. → KEY INSIGHTS - **FDA CRL Transparency Reversal:** The FDA has not released a Complete Response Letter since April 2026, following a citizen's petition filed by law firm Covington & Burling challenging the legality of CRL disclosure. Multiple prior commissioners faced identical legal roadblocks. Investors who relied on CRL detail — such as Replimmune's RP1 review — should anticipate reduced regulatory transparency and adjust information-gathering strategies accordingly. - **Rare Disease Approval Bar Shift:** Agios received FDA priority review acceptance for mitapivat in sickle cell disease despite the drug missing its co-primary endpoint of VOC pain crisis reduction. No Advisory Committee is required. Analysts now assign 70–80% probability of approval for drugs like Replimmune and Agios that previously held 10–20% odds, signaling a materially right-shifted approval environment for orphan and rare disease programs. - **TTR Cardiomyopathy Competitive Landscape:** AstraZeneca and Ionis's eplontersen showed no benefit — including no effect on cardiovascular biomarkers — on top of tafamidis in ATTR cardiomyopathy, with hazard ratios near 1.0. This leaves a three-way market between BridgeBio (Atrubi), Alnylam (Amvutra), and Pfizer (tafamidis). Alnylam's next-gen nucresiran, carrying no Sanofi royalty burden versus Amvutra's 20–30% royalty, becomes a critical pipeline asset to monitor. - **Vertex-Crinetics $9B Acquisition Logic:** Vertex acquired Crinetics for approximately $9B net of cash, gaining palopegteriparatide and adametionine targeting congenital adrenal hyperplasia — a disease on newborn screening panels with 50 years of steroid-based treatment. Neurocrine's Crenessity validated CAH as a large commercial market. The primary risk is liver enzyme elevations seen in adametionine trials; seven mild self-resolving cases were reported, warranting close monitoring through phase three. - **AI in Drug Development — Realistic Near-Term Gains:** Anthropic's Claude for Science targets research workflow efficiency rather than biological discovery breakthroughs. Bristol Myers Squibb cites 5–10% efficiency gains across operations. Vas Narasimhan suggests AI could reduce drug development timelines 30% — from ten years to seven — and double success rates from 8% to 16%. The core limitation remains biology's slow feedback loops versus coding's near-instant validation cycles. - **FDA Institutional Capacity Risk:** DOGE-driven staff reductions preceded Commissioner Makary's tenure, leaving the FDA without experienced reviewers across multiple divisions. The absence of senior champions like Nicole Verdun and Peter Marks creates decision-making gaps particularly damaging for complex rare disease applications such as UniQure's Huntington's program. Investors should factor institutional capacity degradation — not just policy direction — into regulatory timeline and outcome assumptions. → NOTABLE MOMENT The eplontersen trial produced no detectable biological effect on cardiovascular biomarkers on top of tafamidis — not merely a missed p-value but a hazard ratio near 1.0. This directly contradicts Alnylam's Helios-B data showing substantial outcomes benefit with a silencer in a similar population, leaving analysts unable to reconcile the two datasets ahead of ESC. 💼 SPONSORS None detected 🏷️ FDA Rare Disease Approvals, TTR Cardiomyopathy, CRL Transparency, AI Drug Development, Biotech M&A, Alzheimer's Tau Therapy

Read Full SummaryListen
Biotech Hangout

Episode 176 - March 13, 2026

Biotech Hangout
61 minCohost

AI Summary

→ WHAT IT COVERS Biotech Hangout Episode 176 covers macroeconomic risks from Middle East conflict driving oil toward $100/barrel, Vinay Prasad's FDA departure, Servier's $2.5B Day One acquisition, phase three data from Roche and Xenon, IDEA Biosciences' upcoming uveal melanoma readout, and competitive dynamics in NMIBC, IgAN, and obesity markets. → KEY INSIGHTS - **Biotech macro resilience:** Rising oil prices near $100/barrel and potential inflation-driven rate increases pose sector risk, but panelists argue biotech is increasingly insulated due to cash-flow-positive fundamentals and reduced speculative character. Unlike 2021–2023, the sector now trades on near-term data catalysts and product revenues rather than pure pipeline optionality, making it less vulnerable to rate-driven risk-off sentiment than in prior cycles. - **FDA leadership transition:** Vinay Prasad's April departure from CBER creates regulatory uncertainty. Investors should monitor the April 5 Denali PDUFA for Hunter Syndrome as the first real test of post-Prasad FDA flexibility. The ideal successor sits between Peter Marks (too lenient) and Prasad (too stringent), with industry prioritizing predictability and consistency over directional bias in approval standards. - **IDEA Biosciences uveal melanoma catalyst:** Darovacertib, an oral PKC inhibitor combined with crizotinib, has phase two/three top-line PFS data due end of March 2026. Prior phase one/two data showed seven-month median PFS versus two-to-three months for existing standards. A KOL cited 80% probability of success. Accelerated approval pathway is planned if results clear roughly five-and-a-half months, with potential market launch in 2027. - **NMIBC market structure:** The non-muscle-invasive bladder cancer space is shifting toward combination therapies. Ramada's gemcitabine-docetaxel gel formulation showed an 80% one-year complete response rate in high-risk NMIBC, above competitors further along in development. CG Oncology's oncolytic virus is also moving toward a gemcitabine combination BLA. Monotherapy twelve-month CR rates near 50% mean multiple products can coexist commercially across treatment lines. - **Oral SERD competitive dynamics:** Roche's geridesterant failed its Presevera phase three trial in first-line ER-positive HER2-negative metastatic breast cancer when added to palbociclib. The signal suggests oral SERDs may be incompatible with CDK4/6 inhibitor combinations in first-line settings, while retaining utility in ESR1-mutant refractory patients. Investors should focus oral SERD exposure on adjuvant and CDK4/6-free settings rather than first-line combination strategies. - **Drug pricing expansion in biotech:** Otsuka priced its IgAN anti-APRIL antibody at roughly twice analyst expectations, effectively doubling the estimated total addressable market for the class. Vertex's povetacicept data, despite not exceeding the bull case, drove a 10% single-day move in a $100B-plus market cap company. Companies are increasingly pricing to the upside with limited pushback, a dynamic investors should factor into TAM models for late-stage biologics. → NOTABLE MOMENT Panelists noted that J&J repeatedly attacked CG Oncology's dataset in the NMIBC space, claiming significant competitive advantages — yet every major claim ultimately proved incorrect. The situation was described as a rare and uncomfortable instance of a major pharma company aggressively targeting a small biotech and being demonstrably wrong on the clinical data. 💼 SPONSORS None detected 🏷️ FDA Regulation, Oncology Drug Development, Biotech M&A, IgAN Treatment, NMIBC Competitive Landscape, Biotech Macro Risk

Read Full SummaryListen
Biotech Hangout

Episode 173 - February 20, 2026

Biotech Hangout
60 minCohost

AI Summary

→ WHAT IT COVERS Biotech Hangout Episode 173 covers China's record-breaking out-licensing deal surge, FDA instability under Marty Makary and Vinay Prasad including the Moderna vaccine reversal, XBI market sentiment, Keytruda patent protection extending to 2033, and positive phase three data from Compass Pathways in treatment-resistant depression. → KEY INSIGHTS - **China out-licensing acceleration:** China out-licensing deals hit $137.7B in 2025 across 186 transactions, with Novartis, Merck, and GSK among the largest participants. In early 2026 alone, 38 deals totaling $1.3B have closed, with deal sizes up 76% and upfront fees doubled year-over-year. Pharma scouts should expect premium pricing, not arbitrage opportunities, going forward. - **FDA regulatory instability risk management:** Nine companies reported FDA reversals after receiving prior alignment on trial designs, with Vinay Prasad reportedly involved in at least six. Investors and executives should avoid building probability-of-success models contingent on current FDA flexibility policies, as leadership continuity over a four-to-five-year drug development timeline cannot be assumed under present conditions. - **Keytruda patent runway to 2033:** Bloomberg Intelligence patent attorneys, who accurately predicted Humira's 2023 expiry years in advance, now project Keytruda protection through 2033, with formulation patents potentially extending to 2039. This flattens Merck's revenue cliff, preserves capital for M&A, and delays biosimilar competition — with meaningful downstream effects on IO combination trial costs. - **Single-trial FDA approval pathway:** Marty Makary and Vinay Prasad co-authored a New England Journal editorial formalizing one pivotal trial as the FDA's default approval standard, citing existing statutory authority and oncology precedent. Companies should monitor whether regulatory actions align with this stated policy before restructuring development programs around single-trial designs, as implementation remains unproven. - **Psychedelic therapeutics commercial viability:** Compass Pathways reported positive phase three results for COM360 psilocybin in treatment-resistant depression across two trials, with durable response data and manageable safety signals. J&J's Spravato generating approximately $2B annually despite a two-hour in-office dosing requirement signals commercial precedent for psilocybin, which offers longer dose spacing and stronger durability advantages. → NOTABLE MOMENT Following Moderna's refused-to-file letter for its mRNA flu vaccine, Marty Makary was reportedly summoned to the White House, where the president expressed displeasure with the agency's handling of the matter. Within days, the refusal was rescinded — a timeline described as virtually unprecedented in FDA procedural history. 💼 SPONSORS None detected 🏷️ China Biopharma Licensing, FDA Regulatory Policy, mRNA Vaccines, Keytruda Patent Protection, Psychedelic Therapeutics

Read Full SummaryListen
Biotech Hangout

Episode 168 - January 9, 2026

Biotech Hangout
61 minCohost

AI Summary

→ WHAT IT COVERS Biotech Hangout opens 2026 with analysis of strong sector momentum driven by M&A activity, successful IPOs, and positive market sentiment. The XBI trades at 2125, matching November 2021 levels. Discussion covers Revolution Medicine takeover rumors, Actis Pharmaceuticals IPO raising $318 million, emerging obesity mechanisms beyond GLP-1s, and policy concerns including CDC vaccine schedule changes and CMS pricing demonstrations. → KEY INSIGHTS - **M&A Market Dynamics:** Revolution Medicine attracts competing bids from AbbVie and Merck at $28-32 billion valuation, representing premium multiples versus historical oncology deals like Loxo and Array. This follows AstraZeneca's $100 million upfront deal with China's Jacobio for a pan-RAS inhibitor and Lilly's VTYX acquisition. Multiple pan-RAS programs validate the target class, with RevMed's phase 3 pancreatic cancer asset potentially reaching market within two years in high unmet need indication. - **IPO Window Reopens:** Actis Pharmaceuticals prices at $18 versus $16-18 range, raises $318 million including $100 million from partner Lilly, and opens at $27 with 10x oversubscription. The radioligand therapy company uses novel mini-protein discovery platform rather than existing peptides, targeting NECTIN-4 initially. Last private raise was $175 million series B in September 2024 from RA Capital, RTW, Janus Henderson, with additional backing from T. Rowe Price, Avidity, Lilly, Bristol Myers, and Merck ventures. - **Follow-On Financing Surge:** Companies pull secondary offerings earlier than traditional post-JPMorgan timing, with all deals upsizing and trading double-digit percentages above offer price. Crynetics raises capital following Pulsenify launch exceeding consensus with 200 enrollment forms in first full quarter for niche indication, plus positive congenital adrenal hyperplasia phase 2 data showing glucocorticoid reduction. Strong follow-on performance indicates robust capital availability and investor enthusiasm entering 2026. - **Next-Generation TYK2 Inhibitors:** Alumis demonstrates envudacitinib achieves PASI 90 in over 50% of psoriasis patients and PASI 100 in 30-40%, matching J&J's oral IL-23 inhibitor icotrokinra and rivaling biologic efficacy. Takeda's TYK279 shows similar results, reframing oral small molecule potential after Bristol's Sotyktu commercial disappointment. Second-generation TYK2s avoid first-generation liabilities while expanding into psoriatic arthritis, ulcerative colitis, and SLE, with Bristol and Alumis both reporting phase 3 SLE data in 2026. - **Obesity Beyond GLP-1:** Arrowhead raises upsized $625 million following ARO-INHBE phase 2 data showing strong efficacy in diabetic obese patients when combined with tirzepatide, despite minimal monotherapy effect in non-diabetic obesity. The siRNA approach targets visceral adipose tissue and liver fat content through novel pathway distinct from GLP-1 mechanisms. Wave Life Sciences pursues similar strategy. Regulatory pathway remains unclear given combination-dependent efficacy, but market validates novel mechanisms addressing muscle preservation and metabolic health beyond weight loss alone. - **Policy Overhang Persists:** CDC removes six vaccines from recommended pediatric schedule without ACIP discussion, including rotavirus, COVID, influenza, meningococcal, hepatitis A, and reduces HPV to single dose. Insurance coverage remains unchanged, limiting immediate commercial impact. CMS most-favored-nation demonstration announcement generates minimal market reaction, suggesting investors either dismiss implementation probability or underestimate impact. Market resilience to policy headlines creates downside risk if significant pricing reform materializes, as investor desensitization may delay appropriate risk assessment. → NOTABLE MOMENT Zenas BioPharma's obexelimab data for IgG4-related disease showed only 56% flare reduction versus Uplizna's 87% in cross-trial comparison, despite positive headline framing. The CD19/FcRIIb dual-targeting mechanism failed to demonstrate superiority over CD19-only approach, disappointing investors expecting enhanced potency from co-engagement strategy. The company proceeds with FDA and EMA filings, positioning weekly subcutaneous dosing as differentiation versus Uplizna's intravenous administration. 💼 SPONSORS [{"name": "CFGO", "url": ""}, {"name": "Incubate Coalition", "url": ""}, {"name": "FTI Consulting", "url": ""}, {"name": "Catalytic Agency", "url": ""}, {"name": "MISPRO", "url": ""}] 🏷️ Biotech M&A, IPO Markets, TYK2 Inhibitors, Obesity Therapeutics, Drug Pricing Policy, Vaccine Policy

Read Full SummaryListen
Biotech Hangout

Episode 169 - January 16, 2026

Biotech Hangout
59 minCohost

AI Summary

→ WHAT IT COVERS JPMorgan Healthcare Conference 2026 signals positive biotech sentiment with seven-out-of-ten optimism. Limited M&A activity reflects stronger company positions and cash reserves. Key developments include Moderna's improved guidance, obesity drug competition intensifying, FDA flexibility debates continuing, and Lilly's Alzheimer's prevention trial TB3 expected in 2027 generating significant interest across neurodegenerative disease space. → KEY INSIGHTS - **Biotech Market Sentiment:** JPMorgan 2026 conference reveals healthy seven-out-of-ten investor optimism, with drug pricing risk diminished and successful commercial launches rewarding data risk. Specialist hedge funds show increased willingness to deploy capital with IPO window potentially opening in Q1-Q2 2026. Generalist mutual funds expanding beyond momentum large-caps into broader pharma and biotech holdings as S&P 500 valuations appear stretched. - **M&A Market Dynamics:** Reduced M&A announcements at JPMorgan reflect companies holding stronger negotiating positions with adequate cash reserves rather than market weakness. Companies like RevMed demonstrate this shift with sufficient runway from recent Royalty Pharma deals and promising pipeline assets, eliminating urgency to sell. This transition from buyer's market to seller's market benefits venture capital with more IPO exit opportunities anticipated. - **Obesity Drug Competition:** Monthly GLP-1 formulations emerge as next competitive battleground with Pfizer's MedCera acquisition data expected at ADA in June and Amgen completing phase three trials. Market projections reach $115-120 billion by 2030 with oral formulations comprising 25 percent. European cash-pay markets demonstrate strong demand despite lack of government reimbursement, validating $300 monthly price points for sustained consumer adoption. - **FDA Regulatory Uncertainty:** Commissioner National Priority Review Vouchers promise two-month approvals but actual timelines extend longer, with Lilly's oral semaglutide delayed to April 10 versus Q1 expectations. Multiple gene therapy and rare disease companies report alignment failures on single-arm trials and biomarker endpoints despite claimed FDA flexibility. Jazz sells priority review voucher for $200 million, indicating sustained value despite regulatory unpredictability. - **Alzheimer's Prevention Paradigm:** Lilly's TB3 prevention trial targeting pre-symptomatic Alzheimer's patients represents potential paradigm shift for neurodegenerative disease, with 2027 readout reaffirmed. Earlier disease intervention shows progressively larger effect sizes across amyloid beta trials, from moderate-severe failures to meaningful early MCI benefits. Success could validate prophylactic plaque removal approach if safety profile remains clean in asymptomatic populations, fundamentally changing Alzheimer's treatment landscape. → NOTABLE MOMENT Pfizer claims AI contributed significantly to achieving $5.6 billion in cost reductions plus additional manufacturing savings, yet the mechanism remains unclear. The statement raises questions about whether AI enabled headcount reduction, administrative automation, or manufacturing optimization, as most C-suite surveys show companies increasing productivity without cutting staff, contradicting common AI vendor promises about workforce reduction. 💼 SPONSORS [{"name": "CFGO", "url": ""}, {"name": "Incubate Coalition", "url": ""}, {"name": "Syneos Health Communications", "url": ""}, {"name": "FTI Consulting", "url": ""}, {"name": "Catalytic Agency", "url": ""}, {"name": "MISPRO", "url": ""}] 🏷️ JPMorgan Healthcare Conference, GLP-1 Obesity Drugs, FDA Regulatory Policy, Alzheimer's Prevention Trials, Biotech M&A Trends

Read Full SummaryListen

Frequently Asked Questions

What podcasts has Paul Matisse appeared on?

Paul Matisse has appeared on 1 podcast we summarize, including Biotech Hangout — 6 episodes in total. Every appearance is listed below with an AI-generated summary.

Does Paul Matisse appear as a guest speaker on podcasts?

Yes. Paul Matisse has been a guest on 1 show we track, across 6 episodes. Browse each appearance below to read the key takeaways and listen to the original.

Where can I find summaries of Paul Matisse's interviews?

Read AI-generated summaries of all 6 of Paul Matisse's podcast appearances on SignalCast — each with key insights and a link to the full episode.

Never miss Paul Matisse's insights

Subscribe to get AI-powered summaries of Paul Matisse's podcast appearances delivered to your inbox weekly.

Start Free Today

No credit card required • Free tier available